Smallcap 500 Index Hits 52-Week High; Syrma, Strides, Avalon Soar Up to 12%

The Nifty Smallcap index reached a 52-week high of 21,174.60 on the National Stock Exchange in Monday's intra-day trade, rising 0.42% on a day when the wider market was under pressure. The move was broad: 152 stocks in the index gained more than 2%. 

At 2:11 PM, the Nifty Smallcap 500 was up 0.10% while the Nifty 50 was down 0.52%. The divergence is not new. Over the past three months the Smallcap 500 has risen 11%, against a 3.4% gain in the BSE Sensex. 

PC Jeweller, Strides Pharma Science, Syrma, ION Exchange India and Avalon Technologies led the index with intra-day gains of between 10% and 18%. Below them, 36 stocks rose between 5% and 9%, 38 gained 4% each, 35 added 3% each and a further 38 were up 2% each. 

Syrma at a new high on heavy volume 

Syrma's shares rallied 12% to a record ₹1,626.50, with 10.95 million shares, equal to 6% of the company's total equity, changing hands across the NSE and BSE. 

The stock is a direct beneficiary of the policy shift Jefferies describes in its report on the electronics components sector. India, in the brokerage's reading, is pursuing indigenisation in stages. The first Mobile Production Linked Incentive scheme, running from FY21 to FY26, succeeded in getting 99% of phones assembled in India, but the domestic value added remained limited. The Electronics Components Manufacturing Scheme introduced in FY26 is intended to build out the domestic component value chain, and 106 of its 249 projects have been approved. A newer programme, MPMS, launched in August 2026, is aimed at raising mobile value addition and exports, with higher incentives for Indian brands and components. 

The two schemes divide the task between them: ECMS works on backward integration in components, while MPMS targets exports and value addition in Indian-made mobiles. MPMS carries an outlay of ₹62,500 crore over five years; ECMS has ₹40,000 crore over six years. 

On Syrma itself, Jefferies counsels caution. It rates the stock Hold at 57 times earnings following a 105% rise so far this year. 

Strides Pharma up 12% 

Strides Pharma Science climbed 12% to ₹1,185 in intra-day trade, with 2.2 million shares traded on the NSE and BSE combined. 

The company develops, manufactures and markets pharmaceutical products, with an emphasis on high-quality, affordable medicines for global markets. Its specialism is niche, technically complex generic finished dosage formulations that are difficult to manufacture. 

In its FY26 annual report, Strides set out how a deliberate push to spread the business across geographies is now producing measurable results. The United States remains an important pillar, but markets outside the US grew steadily through the year and contributed approximately 46% of revenue in FY26, approaching 50% on a quarterly exit basis. 

The company's portfolio strategy is increasingly built around value-led growth: addressing unmet market needs, strengthening brand equity and sharpening product differentiation. Strides views this as the route to better pricing power and a more resilient, sustainable business. It expects the US to remain a principal growth driver in the coming years, with continued research and development spending supporting future launches. At the same time, the company is concentrating on operational excellence while managing sector challenges such as seasonal shifts in demand and regulatory timelines. 

Why the broader market keeps outperforming 

Stock- and sector-specific buying was visible across the broader market on Monday, and small-cap indices touched fresh intra-day lifetime highs. Geojit Investments attributes the sustained investor confidence in this segment to strong earnings momentum, resilient economic growth and firm domestic demand. 

Motilal Oswal Financial Services makes a similar case from the other direction. The Nifty 50 has been more or less flat over the past year, held back by persistent geopolitical headwinds, concerns about relative valuations and sustained selling by foreign institutional investors, concentrated in index heavyweights. Selected pockets of the small- and mid-cap segment, by contrast, have kept delivering strong earnings growth, carrying the Midcap and Smallcap indices to new all-time highs. With earnings growth accelerating and its breadth widening, the brokerage expects the risk-reward balance to keep improving, which in its view should make India more attractive to foreign institutional investors.